Pallas Health review: there is no monthly plan, only a 12-week prepay

The ‘/mo average’ is a twelve-week charge divided by three

Most telehealth programs offer a ladder: pay monthly, or commit for three months, six months or a year and pay less per month. Pallas offers no ladder. Its funnel renders no cadence selector at all — there is exactly one thing to buy per medication, and it is a twelve-week block. Compounded semaglutide is $139 for the first four weeks, then $597 billed every twelve weeks. Compounded tirzepatide is $179 for the first four weeks, then $897 every twelve weeks. The “$199/mo average” and “$299/mo average” you see advertised are those totals divided by three. They are honest arithmetic on a real number; they are simply not a rate anyone can pay.

Two consequences follow, and the second is the one nobody expects.

First, the cash-flow shape. You pay $139 to start. Four weeks later — not twelve — the renewal cycle begins, and the charge is $597 in a single payment. A reader who budgeted from the “$199/mo” figure is looking at three times that on the second bill, and nothing in the headline prepares them for it. Pallas does send an email reminder before a renewal, which helps, and cancellation is self-serve and free at any time — but the reminder arrives against a number you may not have expected.

Second, twelve weeks is not three months. Pallas anchors renewal “every 12 weeks starting 4 weeks after approval”, which is every 84 days — about 4.35 cycles in a year rather than 4. The advertised average divides by three anyway. Here is what that does to the yearly cost, using only Pallas’s own published numbers and renewal terms.

Year 1 is 52 weeks — one four-week introductory period plus four twelve-week blocks. Steady state is 365.25 ÷ 84 cycles a year. On both molecules the advertised average understates the ongoing rate by about 8.7%. We are not calling that a trick: “12 weeks ≈ 3 months” is ordinary shorthand across this whole industry, and Pallas publishes the renewal cadence plainly enough that the sum above is possible at all — which is more than some programs allow. It is simply the number to budget from.

What Pallas publishes that much of this category does not

Compounded GLP-1 telehealth is a category built on things you cannot check. The two questions that matter most — which pharmacy compounds and ships the drug, and which clinician is signing the prescription — go unanswered more often than not. On thisranking, MyDrHank discloses only that its medication is compounded in an “FDA-registered U.S. pharmacy” and names none. Luvo Health names neither a pharmacy nor a prescribing clinician anywhere on its site. For Sprout Health we could not find a named medical director at all. Others do answer them: Try Ageless names seven pharmacies, and Care Bare Rx, Synergy Rx, Breeze Meds and RxSpan MD each name four — though those four publish one shared list off a common backend, so it is really one answer wearing four brands. Pallas answers both on its own account.

It names six dispensing pharmacies on its clinical page — Belmar Pharmacy, Strive Pharmacy, Epiq Scripts, Casa Pharma Rx, The Pharmacy Hub and Foothills Pharmacy — and explains the difference between 503A pharmacies, which compound for an individual patient against a prescription, and 503B outsourcing facilities, which produce in batches under a different regulatory regime. That paragraph is worth more to a reader than any marketing claim on the site.

It also names two clinicians and publishes their NPI numbers, with links inviting you to verify them in the federal NPPES registry — so we did. Dr. Ana Lisa Carr, MD (NPI 1689841744) is active, with a primary taxonomy of family medicine and licenses in 15 states. Dr. Kelly Tenbrink, MD (NPI 1346482684) is active, in emergency medicine, licensed in Tennessee and Florida. Both are real, current registrations. One caveat on the detail: NPPES confirms Dr. Carr’s family-medicine taxonomy, but the obesity- and addiction-medicine board certifications the site claims for her are not verifiable through that registry and we did not check them elsewhere — treat those as the site’s claim rather than as something we confirmed.

Behind all of it there is an identifiable operator: Brentmoor, Inc., 131 Continental Dr, Suite 305, Newark, DE 19713, reachable on +1 (440) 601-3717 and by email Monday to Friday. Pallas states plainly that it is a technology platform and does not employ medical providers — the care is Lion MD’s, running on the CareValidate clinical-operations platform. Saying so out loud is the correct disclosure, and it is one many competitors leave to the fine print.

One of those six pharmacies has FDA history, and it is closed

Naming your pharmacies means a reader can look them up, so here is what a reader will find. Belmar, the first of the six, received an FDA warning letter issued on 31 March 2023 and posted on 18 April 2023, addressed to “Belmar Pharma Solutions, Drug Depot, LLC., dba APS Pharmacy”, concerning compounding practices. The FDA closed that letter out on 30 October 2023. We are not going to restate what it alleged: that is the FDA’s document to characterize, and paraphrasing an enforcement action would turn a disclosure into a claim of ours.

Two things follow from it. The first is that a letter on a partner pharmacy discloses something; it does not disqualify anyone — a closed-out letter is a matter that the agency considers resolved, and it sits on one of six named partners rather than on the company you would be buying from. Pallas Health itself has no FDA warning letter: we screened the live index in August 2026 under the brand, the domain, the operating entity Brentmoor and the CareValidate platform, and found nothing against any of them. The second is more uncomfortable, and worth saying plainly: we can tell you this only because Pallas published the pharmacy list. The programs that name nobody are not cleaner, they are merely unauditable — and we would rather rank a company whose partners can be checked.

We did not move the score for it. Our 3.9 is a verdict on the product, the pricing structure and the disclosure; the letter above is a fact about a third party that we are reporting rather than weighing.

The fine print that can cost you money

Pallas serves all 50 states and Washington DC, and in 43 of them the whole process is asynchronous — a questionnaire, no appointment. Seven states — Arkansas, Mississippi, New Mexico, North Dakota, Rhode Island, South Dakota and West Virginia — plus Washington DC require one video visit. If you live in one of those and you book that visit, a $60 deposit is taken. Attend, and it is credited to your first order; reschedule properly, and it is refunded in full. Miss it without rescheduling and abandon the intake, and Pallas may keep it. That is the one charge on the whole site that can leave you paying something and receiving nothing.

On refunds: for purchases made on or after 14 July 2026, a $5 fee is deducted from each refunded payment. It is never applied when a clinician declines to prescribe for you, or when an order is not fulfilled — those refund in full. Cancellation itself is free and self-serve through the portal, takes effect at the end of the current billing period, and there is no minimum term. Price changes require at least 30 days’ notice. Shipping is free, and only when something is actually prescribed. Payment is by card through Stripe or over time through Klarna, there is a promo-code field, and a shipping-state guard blocks checkout where the company cannot serve you.

Three more things a careful reader should know. Pallas’s before-and-after “Verified Customer” stories carry the caveat that individuals shown in marketing may be actors or models. Its footer states that some content on the site is AI-generated with no warranty as to accuracy — which is a reason to treat its blog as marketing and to bring any clinical question to a clinician instead. And the site banner says purchases are FSA/HSA eligible, but there is no insurance path of any kind: this is cash-pay, permanently, and the brand-name options it lists alongside the compounded ones ($1,069/mo for Zepbound, $1,299/mo for Ozempic, $1,349/mo for Wegovy and Mounjaro) are priced for someone paying without coverage.

Pallas Health vs a ‘natural GLP-1’ supplement

A supplement and a prescription GLP-1 are not two versions of the same thing. A probiotic like our top-rated pick works at the margins — supporting the gut’s role in appetite and blood-sugar signaling, with modest, realistic effects. A prescribed GLP-1 drug acts directly on the receptor at pharmacological strength; the effect size is in a different league, and so is the side-effect and cost profile. Pallas sits firmly in the second bucket, and the cost gap is the honest way to see it: a twelve-week block of compounded semaglutide costs more than a year of most things on our shelf. Read our supplements vs GLP-1 drugs breakdown before you decide which lane you are in.